**ABSTRACT**

**Background:** The comparison of same, equal and low dose of misoprostol by the oral and vaginal routes for induction of labour at term requires further elucidation.

**Objective:** To compare the efficacy and safety of 25 micrograms (ug) of oral misoprostol with 25ug vaginal misoprostol for induction of labor at term.

**Methods:** A randomised control trial that involved 169 consented women with indication for induction of labor. A total of 85 women had oral misoprostol while 84 women had vaginal misoprostol. The oral misoprostol dose (25ug) was repeated every 2 hours, while the vaginal dose (25ug) was repeated every 6 hours for a maximum duration of 24 hours or when need arose for intervention. Data was analysed using SPSS version 20.

**Results:** The mean induction-delivery interval was significantly shorter (18.48 +/- 2.01 vs. 22.82 +/- 2.50, \( P = 0.00 \)), with more vaginal deliveries (88.2% vs. 85.7%, \( P = 0.00 \)) in the oral group compared to the vaginal group respectively. The cardiotocographic abnormalities in the vaginal group were significantly higher than the oral group (8.3% vs. 1.2%, \( P = 0.03 \)). There were more foetal distress and meconium stained liquor in the vaginal group but not statistically significant.

**Key words:** Efficacy; oral misoprostol; safety; vaginal misoprostol.
Prostaglandins remain the single most effective means of achieving cervical ripening and induction labor, but they should be avoided in cases of scarred uteri and used with caution in grand multipara.[3] Misoprostol unlike dinoprostone is stable at room temperature, cheaper, effective, easy to administer, and can be given through several routes (oral, vaginal, sublingual, rectal, and buccal).[9,10] In 2011, World Health Organization issued guidelines on induction of labor, which includes the use of oral and vaginal misoprostol for induction of labor and is applicable to all clinical settings.[3,9] Similarly, the Federal Ministry Of Health in Nigeria had approved the use of misoprostol for induction of labor and issued guidelines regarding its use.[11]

Oral misoprostol is more effective than intracervical prostaglandins and the current gold standard vaginal dinoprostone in achieving vaginal delivery within 24 h with fewer cesarean sections.[3,9] For women with ruptured membranes, it exhibits similar efficacy to oxytocin.[9] The comparison between oral misoprostol and vaginal prostaglandins favored oral misoprostol with reduced risk of caesarean births and without increase in the risks of adverse maternal or perinatal outcome.[3,9,12] However, dreadful side effects can occur with high dose oral misoprostol, but with low dose the rates were equivalent to both placebo and the current gold standard: vaginal dinoprostone and may be lower compared with vaginal misoprostol.[9] Also, the few local studies done on induction of labor at term were with only vaginal misoprostol, while the majority of international studies done compared the two routes but with high doses of misoprostol (≥50 µg), with associated dreadful side effects of uterine hyperstimulation and tachysystole.[3,7,9-15]

In view of the above evidences that lower dose misoprostol is associated with less dreadful side-effects and the paucity of studies that compared equal and low dose misoprostol via the oral and vaginal route, this study aims to compare the safety and efficacy of 25 µg tablet misoprostol (Vanprazole by Cipla-Evans pharmaceuticals India) administered in equivalent doses via the oral and the vaginal routes.

**Methodology**

**Setting**

The study was conducted in the delivery suite of the Obstetrics and Gynaecology department of Ahmadu Bello University Teaching Hospital Zaria (ABUTH), North Western Nigeria from May 2014 to June 2015. This hospital provides antenatal, intrapartum, postnatal, pediatric inpatient and outpatient care with emergency obstetric and neonatal care. Some local cultural practices like early marriage, early pregnancies with high fertility rate are associated with medical conditions like hypertension in pregnancy, which frequently demand interventions like induction of labor.

**Study population**

The study population were pregnant women of parity less than 5 (para 0 to para 4) admitted into the labor ward with indication for induction of labor at term (38–42 weeks) and who gave a written informed consent.

**Study design**

The study was a randomized controlled trial. It involved eligible, consented patients who were randomly assigned into oral or vaginal misoprostol group. The allocation was done by sequentially opening numbered and folded forms with already stamped routes of administration based on a computer-generated randomization table. The forms were sealed in opaque envelopes and picked at random from a basket by each patient.

**Inclusion criteria**

Women with term singleton fetuses, vertex presentation, a specific indication for induction of labor, parity of zero to four, Bishop score of zero to five, and cardiotocographic evidence of a reactive fetal cardiac activity.

**Exclusion criteria**

Women with multiple gestation, malpresentation, nonreactive fetal cardiac activity, previous uterine surgeries, those already in labor, women with medical conditions, such as sickle cell anemia, mitral valve stenosis, glaucoma, and known hypersensitivity to prostaglandins.

**Materials and Procedure**

A written informed consent was obtained from every participant. Demographic data of the women including age, parity, reason for induction, gestational age, and admitting Bishop Score were recorded. Routine clinical evaluation and laboratory investigations including urinalysis, hematocrit, and at least one pint of compatible blood were obtained. A preliminary cardiotocographic (CTG) was done to assess the fetal condition, while a repeat CTG was done whenever abnormality in the FHR was detected and more frequently in the high-risk patients.

The 25 µg misoprostol (by Pantoprazole Cipla-Evans pharmaceuticals, India) was given to each participant in the oral group to be swallowed every 2 h with 20 ml of Nestle water, under direct observation for a maximum of 24 h (12 doses). The vaginal study group received similar dose of misoprostol
(25 µg) placed in the posterior vaginal fornix every 6 h for a maximum of 24 h (four doses). However, the next dose of misoprostol was withheld and the process terminated if the parturient transits into active phase of labor or when untoward observation was made requiring intervention, such as fetal distress, vaginal bleeding, or uterine hyperstimulation (a contraction lasting at least 2–3 min or more than five contractions per 10 min lasting greater than 45 s).

The interval from the last dose of misoprostol was at least 6 h before labor augmentation with oxytocin was considered, whenever it was adjudged necessary. Induction of labor was declared failed when active labor was not established after 24 h or the process abandoned (prior to onset of active labor) due to maternal or fetal complication. The woman was then given option for induction of labor after resting and further evaluations or an alternative mode of delivery based on the prevailing obstetric and clinical conditions. For women who proceeded into active phase of labor, partographs were opened and duly completed as their labor progressed.

Each parturient was monitored for uterine hyperstimulation, nausea, vomiting, diarrhea, fever, need for analgesia, genital tract lacerations, primary postpartum hemorrhages, need for intensive care admission, and fetal complications like cardiotocographic changes, meconium stained liquor, fetal distress, fetal demise, still birth, birth asphyxia, and need for admission into the special care baby unit (SCBU).

The efficacy outcomes of the induction were recorded as induction – delivery interval unchanged cervix after 24 h, need for oxytocin augmentation, vaginal delivery not achieved within 24 h, operative vaginal deliveries, caesarean section rates, cumulative doses of misoprostol needed, and duration of latent phase of labor and retained placentae.

Besides standard management of patient in labor, uterine contractions, pulse, and FHR were recorded hourly in latent phase and 1/4 hourly in the active phase of labor. CTG was repeated whenever abnormal FHR (<120 or >160 bpm) was observed with the sonicaid and more frequently in the high-risk pregnancies (such as bad outcome in previous pregnancy and gestational diabetes) and in those with evidence of fetal distress. The partograph was opened for each parturient as soon as they commenced active phase of labor and ensuing first, second, third, and fourth stages of labor were managed according to the departmental and national labor management protocols.

**Sample size**

The minimum sample size was determined by using the proportion outcome formula for a two-sided test of 5%:

\[ m = c \times \frac{\pi_1(1-\pi_1) + \pi_2(1-\pi_2)}{(\pi_1 - \pi_2)^2} \]

Where

- \( m \) = Size per group
- \( c = 7.9 \) for 80% power

The proportion estimates were taken as:

- \( \pi_1 = 0.82 \) and \( \pi_2 = 0.62 \), when the proportion of women that achieved a vaginal delivery on induction with vaginal misoprostol from previous Zaria study was taken as 82% (28/34) at a power of 80% to obtain a proportion difference of 20% (i.e., 62%) between the two groups given a statistical significance of 0.05.

Thus, \( m \) (size per group) = 7.9 \times \frac{(0.82(1-0.82) + 0.62(1-0.62))}{(0.82 - 0.62)^2} = 75.68

Size per the two groups = 76 \times 2 = 152

The minimum of 167 subjects was needed, when an attrition rate of 10% was added to the calculated sample size. Thus, a total of 170 subjects were randomized.

**Data analysis**

Data was analyzed using Statistical Packages for Social Science (SPSS) version 20 software. The mean induction delivery interval and other efficacy outcomes were compared using the student t-test. Complications of misoprostol due to different routes of administration were analyzed by their percentages and compared by Fisher’s test of proportions. A \( P \) value of < 0.05 was considered statistically significant.

**Ethical consideration**

Approval for this study was obtained from the Ethical Committee of Ahmadu Bello University Teaching Hospital Shika, Zaria.

**Funding**

All the expenses incurred in carrying out this study were borne by the researcher.

**Results**

A total of 1,383 deliveries were conducted during the study period. Among the 192 women slated for induction of labor, 170 were eligible at the point of entry into the study. However, one woman defaulted after allocation into the vaginal group, leaving 169 to receive treatment (an attrition...
rate of less than 1%). A total of 85 pregnant women had 25 µg oral misoprostol and 84 had 25 µg vaginal misoprostol. The induction rate using misoprostol was 12.22% [Figure 1].

The gestational age, bishop score, and parity of the pregnant women were within the same mean and standard deviation of the mean for both groups. These parameters were restricted by the study design (gestational age: 38–42 weeks, Bishop score: 0–5, and parity: 0–4). The mean Bishop score was not significantly different for both groups: 2.93 and 2.90 in the oral and vaginal groups, respectively [Table 1].

The commonest indication for induction of labor was prolonged pregnancy (83.5% and 78.5%) in both the oral and vaginal groups, respectively. The second commonest indication for induction of labor for both routes was pregnancy-induced hypertension (15.3% vs. 17.9%).

The mean duration of labor was not significantly different for both routes (9.80 ± 1.06 vs. 10.45 ± 1.14, \( P = 0.18 \)) for the oral and vaginal routes, respectively. The main indication - delivery interval was significantly shorter in the oral group compared to the vaginal group (18.48 ± 2.01 vs. 22.82 ± 2.50, \( P < 0.001 \)). The need for oxytocin augmentation was nearly the same for both groups. More doses of misoprostol were required to achieve delivery in the oral group than the vaginal (4.66 ± 0.51 vs. 2.62 ± 0.29, \( P = 0.00 \)), respectively [Table 2].

The number of women who delivered by spontaneous vaginal delivery was significantly higher in the oral group compared to the vaginal group (relative risk, RR = 1.20; 95% confidence interval, CI: 0.97–1.49, \( P = 0.00 \)). On the contrary, the cesarean section rate was significantly higher in the vaginal group when compared to the oral route. The main indication for caesarean section was fetal distress, but not statistically significant between the two groups. The percentage of failed induction of labor was not significantly different in both groups [Table 3].

There was a significant difference in the cardiotocographic (CTG) changes (three variable decelerations, two early decelerations, one late deceleration, and one sinusoidal tracing in the vaginal group against one variable deceleration in the oral group (RR = 0.14; 95% CI: 0.02–1.12 \( P = 0.03 \)). More meconium stained liquor, fetal distress, and SCBU admissions were noted in the vaginal group.

The major indication for the neonatal admissions was birth asphyxia (more from the vaginal group), whereas the other two SCBU admissions were due to neonatal jaundice (from oral group) and risk of neonatal sepsis (from vaginal group). There was no uterine hyperstimulation, intensive care unit admission, maternal death or still birth in both groups. One woman had primary postpartum hemorrhage from a cervical tear in the vaginal group. Maternal gastrointestinal complications were not significantly different between the two groups. One woman in the oral group had diarrhea as the side effect, whereas another woman in the vaginal group had nausea. The need for analgesia was also not significantly different for both routes [Table 4].

| Table 1: The characteristics of the pregnant women who had induction of labor with 25 µg misoprostol by the oral and vaginal routes |
|-----------------|-----------------|-----------------|-----------------|------|
| Outcome | Oral group (mean±SD) | Vaginal group (mean±SD) | CI (95%) | \( P \) |
| Age | 28.86±3.15 | 28.37±3.11 | (25.47-28.76) | 0.43 |
| Height | 1.64±0.18 | 1.63±0.18 | (1.61-1.66) | 0.62 |
| Weight | 77.61±8.47 | 76.76±8.43 | (71.65-85.47) | 0.74 |
| Parity | 2.19±0.24 | 1.86±0.21 | (0.88-2.18) | 0.10 |
| Gestational age | 38.19±4.28 | 38.71±4.25 | (38.24-41.17) | 0.66 |
| Bishop score | 2.93±0.32 | 2.90±0.32 | (2.47-3.35) | 0.86 |

| Table 2: Comparison of the efficacy of both the oral and vaginal routes of administration of misoprostol |
|-----------------|-----------------|-----------------|------|
| Oral routes (mean±SD) | Vaginal routes (mean±SD) | \( P \) |
| Duration of labor | 9.80±1.06 | 10.45±1.14 | 0.18 |
| Induction delivery interval | 18.48±2.01 | 22.82±2.50 | 0.00 |
| Oxytocin augmentation | 1.53±0.18 | 1.58±0.17 | 0.77 |
| No. of doses of misoprostol | 4.66±0.51 | 2.62±0.29 | 0.00 |

| Table 3: Outcome of induction of labor following misoprostol administration by the oral and vaginal routes |
|-----------------|-----------------|-----------------|------|
| Outcome | Oral route, \( n = 85 \) | Vaginal route, \( n = 84 \) | RR (95% CI) | \( P \) |
| Spontaneous vaginal deliveries | 75 (88.2) | 72 (85.7) | 1.20 (0.97-1.49) | 0.00 |
| Cesarean section | 10 (11.8) | 12 (14.3) | 1.04 (0.18-1.22) | 0.00 |
| Failed induction of labor | 9 (10.6) | 10 (11.9) | 1.10 (0.47-2.57) | 0.22 |

| Table 4: Fetal and maternal complications following misoprostol administration by oral and vaginal routes |
|-----------------|-----------------|-----------------|------|
| Parameters | Oral route, \( n = 85 \) | Vaginal route, \( n = 84 \) | RR (95% CI) | \( P \) |
| Mecconium stained liquor | 1 (1.2) | 2 (2.4) | 0.49 (0.05-5.35) | 0.55 |
| *CTG changes | 1 (1.2) | 7 (8.3) | 0.14 (0.02-1.12) | 0.03 |
| Fetal distress | 3 (3.5) | 8 (9.5) | 0.37 (0.10-1.35) | 0.11 |
| Apgar score <7 at 5 min | 1 (1.2) | 2 (2.4) | 0.63 (0.05-6.65) | 0.16 |
| SCBU admission | 2 (2.4) | 3 (3.6) | 1.84 (0.32-10.47) | 0.72 |
| Birth asphyxia | 3 (3.5) | 5 (6.0) | 3.68 (0.40-33.98) | 0.22 |
| Need for analgesia | 15 (17.6) | 15 (17.6) | 0.99 (0.52-1.90) | 0.97 |

\*CTG = Cardiotocographic changes: 3 variable decelerations, 2 early decelerations, 1 late deceleration, and 1 sinusoidal tracing in the vaginal group, whereas in the oral group only one variable deceleration. SCBU = Special care baby unit.
Discussion

Literature has shown that the route of administration of misoprostol has a strong impact on the pharmacokinetic profile that results in different clinical efficacy with bioavailability of the oral misoprostol declining after 2 h and that of vaginal misoprostol detectable after 6 h.[34] Therefore, this study used the protocol for oral dosing of misoprostol every 2 h and vaginal dosing every 6 h.[3,16] Kundodyiwa et al. in a systematic review that used the same low and equal dose misoprostol (20 µg) via the oral and vaginal route reported significant differences in terms of less uterine hyperstimulation with FHR changes in the oral group but with no significant differences in other outcomes.[17]

Prolonged pregnancy was the most common indication for induction of labor as similarly reported by Bako et al. and Ekele et al.[13,18] However, an earlier Zaria study by Abdul et al. reported hypertension in pregnancy as the commonest indication unlike the present study where hypertension in pregnancy was the second commonest indication. This disparity could be explained by the fact that only term pregnancies were used in this study, whereas the modal gestational age of the women with pregnancy-induced hypertension in the previous study was 36 week gestation.[14]

A shorter induction delivery- interval for the oral route was similarly reported by Kombhampati et al. and Shetty et al. However, Rasheed et al. and Shetty et al. reported shorter induction delivery interval for the vaginal route against the oral route.[20,21] These variations in the induction delivery interval can be explained by the lack of homogenicity in the dosing frequency for the oral route. For example, the same doses of 50 µg were used for both the oral and the vaginal routes by Rasheed et al. but their dosing frequency was every 4–6 h, which was too long for the bioavailability of the oral drug of just 2 h.[20]

Other parameters like Bishop scores, gestational ages, and parity can affect the induction delivery interval if not carefully selected as in this study.[8] However in this study, these parameters were restricted by the study design (gestational age: 38–42 weeks, Bishop score: 0–5, and parity: 0–4). Similar to the report by Khadija et al. the mean gestational age, Bishop score and parity for both routes in this study were comparable with no significant difference.[22]

The more number of doses of oral misoprostol administered in this study was similar to the findings of Rasheed et al., Khadija et al., and Shetty et al.[22,20] However, differ from that of Hall et al. who reported consistency in the number of doses for both routes of administration, which can be explained by the use of a higher oral dose (100 µg) compared to a lower vaginal dose (25 µg).[23] The study by Khadija et al. showed similar needs for oxytocin augmentation for both routes of misoprostol administration.[22] However, Shetty et al. and Rasheed et al. showed more oxytocin requirement for the oral route than the vaginal route.[20,21] Both Rasheed et al. and Shetty et al. used a dosing frequency (4 hourly) which could not keep up to the recommended levels in the plasma to maintain contractions and hence the need for additional oxytocin augmentations in order to achieve deliveries. The oral route of misoprostol exhibits less bioavailability and requires more frequent dosing (2 hourly) to maintain the plasma peak volume required to sustain the adequate number of contractions needed.[24]

The higher success rate in achieving vaginal deliveries in the oral route compared to the vaginal was similarly reported by Kombhampati et al., Ratna et al., and Sultana et al.[24,25] However, caesarean section rate was significantly lower in the oral group compared to the vaginal group which was similar to the report by Kombhampati et al., Ratna et al., and Sultana et al.[19,24,25]

More cesarean sections were done in the vaginal group on account of fetal distress as similarly reported by Kombhampati et al.[19] This can be explained by the greater bioavailability of the vaginal dose of misoprostol.[16]

Regarding fetal safety outcomes, Kombhampati et al. similarly reported more clear liquor in the oral group compared to the vaginal group as in this study, where more meconium stained liquor was seen in the vaginal group.[19] The meconium stained liquor could be explained by the longer bioavailability of the vaginal route of administration of misoprostol which had been associated with uterine hyperstimulation, fetal distress, and meconium stained liquor.[16,19] Contrary, the Cochrane review showed more meconium stained liquor in the oral group.[26] However, meconium staining has been associated with prolonged pregnancy rather than the mode of the induction.[19]

The significant higher rate of cardiotocographic changes in the vaginal group compared to the oral group was similarly reported by Khadija et al.[22] Similarly, most studies reported increased rate of fetal distress in the vaginal group and uterine hyperstimulation.[3,21,26] The overall fetal safety outcomes were better with the oral route. Similarly, more safer fetal outcomes with the oral route were reported by Kombhampati et al., Ratna et al., and Khadija et al.[22,19,24] When the safety outcome of induction of labor with misoprostol is been contemplated upon, then the oral route has proved by this research and many others to be the safer option.
Maternal gastrointestinal side-effects of misoprostol were not common in this study as reported by most studies, where diarrhea is the most common side effect of the oral route. This could probably be due to the low dose used (25 μg) in this research.

Conclusion

The oral route of administration of misoprostol (25 μg) for the induction of labor at term is more effective than the vaginal route, by virtue of the higher rates of vaginal deliveries, lower rate of cesarean section, and shorter induction delivery interval. The oral route is also safer than the vaginal route for fetuses.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Limitations of the study

1. The neonates were not followed-up over a long-term period, in order to detect the rare and remote side effects that maybe related to the misoprostol.
2. The method of analgesia used in the process of the induction of labor was intramuscular pentazocine unlike most international studies that used epidural analgesia for pain alleviation during labor induction.

Recommendations

1. The 25 μg misoprostol should be added to the essential drug list in our settings, to discourage the breaking of 200 μg misoprostol, or dissolving it in water before use.
2. The administration of the 25 μg oral dose of misoprostol, for induction of labor, can be a better choice in centers where continuous fetal monitoring cannot be ensured.
3. The dosing regimen (25 μg every 2 h) for the oral route should be adhered to, rather than a higher oral dose with a longer dosing interval: for example 50 μg every 4 h to comply with bioavailability of the oral route.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Managing Complications in Pregnancy And Childbirth: A Guide For Midwives and Doctors. 2nd ed. World Health Organization; 2003. Available from: https://www.who.int/maternal_child_adolescent/documents/managing-complications-pregnancy-childbirth/en/. [Last accessed on 2019 Jul 25].
2. Fawole B, Wafiou I, Machoki M, Wolomby M, Jean J, Mugerwa K. Unmet need for induction of labour in Africa: Secondary analysis from the 2004-2005 WHO global maternal and perinatal health survey. BMC Public Health 2012;25:722.
3. WHO Recommendations for induction of labour. Geneva: World Health Organization. 2011. Available from: https://whqlibdoc.who.int/publications/2011/9789241501156eng.pdf. [Last accessed on 2019 Jul 25].
4. Global Survey on Maternal and Perinatal Health: Induction of Labour Data. Geneva: World Health Organization; 2010. Available from: http://www.who.int/reproductivehealth/topics/best_practices/global_survey. [Last accessed on 2019 Jul 25].
5. Gulmezoglu AM, Crowther CA, Middleton P, Heatley E. Induction of labour for improving birth outcomes for women at or beyond term. Cochrane Database Syst Rev 2012;6:CD004945.
6. World Health Organization Global Survey on Maternal and Perinatal Health Research Group. Factors and outcomes associated with the induction of labour in Latin America. BJOG 2009;116:1762-72.
7. Tan PC, Suguma S, Vallikkunnu N, Hassan J. Predictors of newborn admission after labour induction at term: Bishop score, pre-induction ultrasonography and clinical risk factors. Singapore Med J 2008;49:193-8.
8. Caio AC, Edward A (jnr), Geraldo D, Silvana MQ, Gabriele T, Ricardo CC, et al. Predicting success of labour induction in singleton term pregnancies by combining maternal and ultrasound variables. J Matern Foetal Neonatal Med 2016;21:3511-18.
9. Abdel-Aleem H. Misoprostol for Cervical Ripening and Induction of Labour: The WHO Reproductive Health Library; Geneva: 2011. Available from: http://apps.who.int/whr/pregnancy_childbirth/induction/ CD000941_abdel-aleemh_com/en/. [Last accessed on 2019 Jul 25].
10. Shagufa P, Zaffar AK, Mufti SM, Shah MA, Visahl RT, Hakak S, et al. Comparison of sublingual, vaginal, and oral misoprostol in cervical ripening for first trimester abortion. Indian J Pharmacol 2011;43:172-5.
11. The Federal Ministry of Health. National Guidelines And Standards For The Use Of Misoprostol In Nigeria. Guidelines And Protocols For The Clinical Use Of Misoprostol In Obstetrics And Gynaecology At The Facility Level. FMOH. 2012:19-20.
12. Prameela, Sharma KD. Comparison between use of oral misoprostol versus vaginal misoprostol for induction of labour at term. J Obstet Gynecol India. 2018;68:88-92.
13. Bako BG, Obed JY, Sanusi I. Methods of induction of labour at the university of Maiduguri teaching hospital, Maiduguri: A 4+ year review. Niger J Med 2008;17:139-42.
14. Abdul MA, Ibrahim UN, Yusuf MD, Musa H. Efficacy and safety of misoprostol in induction of labour in a Nigerian tertiary hospital. West Afr J Med 2007;26:213-6.
15. Ibrahim IA, Obilahi A, Ekine AA. The Safety of induction of labour in the Niger Delta Region. Greener J Med Sci 2012;2:173-8.
16. Tang OS, Gemzell-DK. Misoprostol: Pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet 2007;99:S160-7.
17. Kundodyiwa TW, Alfirevic Z, Weeks AD. Low-dose oral misoprostol for induction of labour: A systematic review. Obstet Gynecol 2009;113:374-83.
18. Ekele BA, Nnadi DC, Gana MA, Shehu CE, Ahmed Y, Nwobodo EI. Misoprostol use for cervical ripening and induction of labour in a Nigerian teaching hospital. Nijer J Clin Pract 2007;10:234-7.
19. Kombhampati K, Meherlatha R, Iqbal JQ, Suneetha B, Ramya V. Comparative study of oral and vaginal misoprostol for induction of labour: Material and foetal outcome. J Clin Diagn Res 2013;7:2866-9.
20. Rasheed R, Alam AA, Younus S, Raza F. Oral versus vaginal misoprostol for labour induction. J Pak Med Assoc 2007;57:404-7.
21. Shetty A, Livingstone J, Acharya S, Danielian P, Templeton A. Oral misoprostol versus vaginal misoprostol in term labour induction. A randomized comparison. Acta Obstet Gynecol Scand 2003;82:1103-6.
22. Khadija B, Mahjabeen S, Zulfiqar B. To compare the safety and efficacy of misoprostol through oral and vaginal routes for induction of labour at term. Int J Surg Pak 2009;14:38-41.
23. Hall R, Duarte GM, Harlass F. Oral versus vaginal misoprostol for labor induction. Obstet Gynecol 2002;99:1044-48.
24. Ratna K, Jyoti S, Arhana A. Oral: Vaginal misoprostol: Which route for induction of term labour. N J Obstet Gynecol 2007;2:23-28.
25. Alfirevic Z, Allafiel N, Weeks A. Oral misoprostol for induction of labour. Cochrane database of systematic reviews 2014. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001338.pub3/epdf/standard. [Last accessed on 23 Jul 2019].
26. Rasheed R, Alam AA, Younus S, Raza F. Oral versus vaginal misoprostol for labour induction. J Pak Med Assoc 2007;57:404-7.